Bad Pharma

About the book

Bad Pharma takes the machinery of medicine as its subject: clinical trials, regulatory review, publication, marketing and the gaps between them. Goldacre, a physician and journalist, builds the book around a plain question. How much of what is known about a drug actually reaches the people who prescribe it? The book diagnoses problems in how medicine is tested and sold, then argues about repairs.

The territory is broad but concrete. Trials can go unpublished when results are unfavorable. Data can be withheld from independent researchers. Drug approval can rest on thin or poorly reported evidence. Marketing can shape prescribing in ways that have little to do with patient benefit. Goldacre draws on the published literature, regulatory documents and public disputes to show how these practices work, rather than treating them as isolated scandals.

The book sits in a tradition of medical skepticism that treats evidence as something to be audited, not trusted by default. Its target is the system that produces and circulates drug evidence, including journals, regulators, industry and the medical profession itself. Goldacre writes as an insider who wants the machinery fixed, not abandoned.

How to read it

Approach this as an argument built from cases and documents. Goldacre moves between specific examples and general claims, and the force of the book comes from seeing the pattern across many examples. Keep track of which claims rest on published studies, which on regulatory records and which on his own interpretation. The prose is brisk and often funny, but the subject is technical in places, especially around trial design and reporting.

Readers new to evidence-based medicine may want a basic grasp of what a randomized controlled trial is and why publication matters before starting. The book rewards attention to its footnotes and sources, which carry much of the evidentiary weight. It is a polemic with a reform agenda, and it is most useful when read with that stance in view.

Who it suits

Patients who want to understand why their doctor may not know everything about a drug will find the book clarifying. Medical students, junior doctors and researchers will get a useful map of the incentives and failures that shape the evidence they rely on. Journalists covering health and policy staff working on regulation will find concrete cases and a framework for asking better questions. General readers curious about how medical knowledge is made will also find it accessible, provided they accept its argumentative style.

Reading considerations

The book was published in 2012, and its examples and regulatory details reflect that period; some specific cases and rules have since changed, so treat dated claims as historical context rather than current fact. Goldacre argues forcefully and selects cases to make his case, which is appropriate for a polemic but means readers should seek out responses and later reporting. The book is not a guide to individual treatment decisions, and it should not be used as one.